iRhythm Technologies Dirección

Dirección controles de criterios 1/4

El CEO de iRhythm Technologies' es Quentin Blackford , nombrado en Oct 2021, tiene una permanencia de 2.5 años. compensación anual total es $16.60M, compuesta por 4.1% salario y 95.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.23% de las acciones de la empresa, por valor de $8.10M. La antigüedad media del equipo directivo y de la junta directiva es de 1.9 años y 6.8 años, respectivamente.

Información clave

Quentin Blackford

Chief Executive Officer (CEO)

US$16.6m

Compensación total

Porcentaje del salario del CEO	4.1%
Permanencia del CEO	2.6yrs
Participación del CEO	0.2%
Permanencia media de la dirección	1.9yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Quentin Blackford en comparación con los beneficios de iRhythm Technologies?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$130m
Dec 31 2023	US$17m	US$677k	-US$123m
Sep 30 2023	n/a	n/a	-US$105m
Jun 30 2023	n/a	n/a	-US$99m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$8m	US$650k	-US$116m
Sep 30 2022	n/a	n/a	-US$128m
Jun 30 2022	n/a	n/a	-US$131m
Mar 31 2022	n/a	n/a	-US$124m
Dec 31 2021	US$10m	US$163k	-US$101m

Compensación vs. Mercado: La compensación total de Quentin($USD16.60M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD2.61M).

Compensación vs. Ingresos: La compensación de Quentin ha aumentado mientras la empresa no es rentable.

CEO

Quentin Blackford (44 yo)

2.6yrs

Permanencia

US$16,595,149

Compensación

Mr. Quentin S. Blackford serves as an Independent Director of Paragon 28, Inc. since August 1, 2022. He serves as President and Chief Executive Officer since October 04, 2021 and serves as Director at iRhy...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Quentin Blackford	President	2.6yrs	US$16.60m	0.23% $ 6.4m
Brice Bobzien	Chief Financial Officer	1.8yrs	US$5.28m	0.0085% $ 235.7k
Minang Turakhia	Chief Medical & Scientific Officer and Executive VP of Product Innovation	2.1yrs	US$5.32m	0.011% $ 308.7k
Patrick Murphy	Chief Business & Legal Officer	2.4yrs	US$5.33m	0.031% $ 849.6k
Chad Patterson	Chief Commercial Officer	1.8yrs	US$5.77m	0.017% $ 474.2k
Mervin Smith	Executive Vice President of Business Operations	less than a year	sin datos	sin datos
Marc Rosenbaum	Senior VP of Finance & Chief Accounting Officer	less than a year	sin datos	sin datos
Daniel Wilson	Executive VP of Corporate Development & Investor Relations	4.9yrs	US$3.54m	0.098% $ 2.7m
Douglas Devine	Executive Advisor	1.2yrs	US$2.72m	0.055% $ 1.5m
Sumi Shrishrimal	Executive VP & Chief Risk Officer	2yrs	sin datos	0.079% $ 2.2m
Stephanie Zhadkevich	Director of Investor Relations	no data	sin datos	sin datos

1.9yrs

Permanencia media

44yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0A7L no se considera experimentado ( 1.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Quentin Blackford	President	2.3yrs	US$16.60m	0.23% $ 6.4m
Ralph Snyderman	Independent Director	6.8yrs	US$233.12k	0.028% $ 773.2k
Michael Mirro	Medical Director & Member of Scientific Advisory Board	no data	sin datos	sin datos
Bruce Bodaken	Independent Director	6.8yrs	US$240.25k	0.026% $ 715.4k
Abhijit Talwalkar	Independent Chairman	8yrs	US$286.74k	0.029% $ 803.9k
R. Mead	Medical Director & Member of Scientific Advisory Board	no data	sin datos	sin datos
James Quinn	Member of Scientific Advisory Board	no data	sin datos	sin datos
Cathleen Noel Merz	Independent Director	6.1yrs	US$230.62k	0.014% $ 389.2k
Mark Rubash	Independent Director	8.2yrs	US$248.12k	0.030% $ 817.5k
Mehdi Razavi	Medical Director & Member of Scientific Advisory Board	no data	sin datos	sin datos
Karen Ling	Independent Director	2.5yrs	US$239.97k	0.011% $ 314.3k
Jay Alexander	Medical Director & Member of Scientific Advisory Board	no data	sin datos	sin datos

6.8yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de 0A7L se considera experimentada (6.8 años de antigüedad promedio).

iRhythm Technologies Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

President recently sold US$3.0m worth of stock

Insider recently sold US$746k worth of stock

iRhythm Technologies, Inc. Announces Director Appointments

Executive VP & Chief Risk Officer recently sold US$124k worth of stock

COO & Secretary recently sold US$415k worth of stock

Recent updates

First quarter 2024 earnings released: US$1.47 loss per share (vs US$1.29 loss in 1Q 2023)

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q1, 2024 Results on May 02, 2024

New minor risk - Profitability

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

New minor risk - Shareholder dilution

President recently sold US$3.0m worth of stock

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against iRhythm Technologies, Inc

iRhythm Technologies, Inc. Revises Revenue Guidance for the Year 2024

iRhythm , Inc. Announces Results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events

Insider recently sold US$746k worth of stock

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.89 loss per share (vs US$0.71 loss in 3Q 2022)

iRhythm Technologies, Inc. to Report Q3, 2023 Results on Nov 02, 2023

iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor

iRhythm Technologies, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$0.80 loss in 2Q 2022)

Now 20% undervalued

iRhythm Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

iRhythm Technologies, Inc. Announces Director Appointments

Executive VP & Chief Risk Officer recently sold US$124k worth of stock

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$1.29 loss per share (vs US$1.71 loss in 1Q 2022)

Now 20% undervalued

COO & Secretary recently sold US$415k worth of stock

Now 21% undervalued

Full year 2022 earnings released: US$3.88 loss per share (vs US$3.46 loss in FY 2021)

iRhythm Technologies, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Chief Legal Counsel recently sold US$182k worth of stock

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2022

iRhythm Technologies, Inc. to Report Q3, 2022 Results on Nov 01, 2022

iRhythm Technologies, Inc. Reiterates Revenue Guidance for the Year 2022

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.59 loss in 2Q 2021)

iRhythm Technologies, Inc. Appoints Brice Bobzien as Chief Financial Officer, Effective August 8, 2022

iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System

iRhythm Technologies, Inc. Announces Management Changes

Executive Vice President of Strategy recently sold US$156k worth of stock

Independent Director recently sold US$56k worth of stock

First quarter 2022 earnings released: US$1.71 loss per share (vs US$0.95 loss in 1Q 2021)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Fiscal Year 2022

iRhythm Technologies, Inc. to Report Q1, 2022 Results on May 05, 2022

iRhythm Technologies, Inc., Annual General Meeting, May 26, 2022

iRhythm Technologies, Inc. Announces the Results of Three Clinical Research Studies Presented At the American College of Cardiology’s 71 Annual Scientific Session & Expo

Consultant & Director recently sold US$904k worth of stock

iRhythm Technologies, Inc. Announces the Results of the KP-Rhythm2 Study

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

COO, CFO & Secretary recently sold US$557k worth of stock

iRhythm Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.17 loss in 3Q 2020)

Insufficient new directors

Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.75 loss in 2Q 2020)

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2021

iRhythm Technologies, Inc.(NasdaqGS:IRTC) dropped from Russell 2000 Growth-Defensive Index

iRhythm Technologies Continues to Fuel Innovation in Cardiac Monitoring and Unveils Two FDA Clearances for Superior Patient Care

iRhythm Technologies, Inc. Provides Earnings Guidance for the First Quarter of 2021

First quarter 2021 earnings released: US$0.95 loss per share (vs US$0.34 loss in 1Q 2020)

Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against iRhythm Technologies, Inc

Full year 2020 earnings released: US$1.58 loss per share (vs US$2.16 loss in FY 2019)

Revenue beats expectations

Study Published in Jama Cardiology Finds Zio by iRhythm Proactively Identifies Atrial Fibrillation, Increases Detection Tenfold

Análisis de compensación del CEO

CEO